Mosaic ImmunoEngineering (CPMV) Return on Invested Capital (2024 - 2026)

Mosaic ImmunoEngineering's Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Invested Capital rose 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (up 1.0% YoY), while the FY2025 annual figure was 0.03%, changed N/A from the prior year.
• Return on Invested Capital for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Invested Capital was 0.01% in Q1 2026, with the low at 0.04% in Q4 2024.
• The 3-year median for Return on Invested Capital is 0.01% (2025), against an average of 0.02%.
• The sharpest annual moves came in 2025 and 2026: Return on Invested Capital grew 3 bps in 2025, then rose 1 bps in 2026.
• Mosaic ImmunoEngineering's Return on Invested Capital stood at 0.04% in 2024, then soared by 80 bps to 0.01% in 2025, then grew by 3 bps to 0.01% in 2026.
• Business Quant data shows CPMV's Return on Invested Capital at 0.01% in Q1 2026, 0.01% in Q4 2025, and 0.01% in Q3 2025.